Laura B Moroney1,2, Jennifer Helios1, Elizabeth C Ward2,3, Jane Crombie1, Anita Pelecanos4, Clare L Burns1,2, Ann-Louise Spurgin1, Claire Blake5, Lizbeth Kenny1,5,6, Benjamin Chua1,5,6, Brett G M Hughes1,5,6. 1. Department of Speech Pathology and Audiology, Royal Brisbane and Women's Hospital, Brisbane, Australia. 2. The University of Queensland, School of Health and Rehabilitation Sciences, Brisbane, Australia. 3. Centre for Functioning and Health Research, Metro South Hospital and Health Service, Brisbane, Australia. 4. QIMR Berghofer Medical Research Institute, Brisbane, Australia. 5. Department of Nutrition and Dietetics, Royal Brisbane and Women's Hospital, Brisbane, Australia. 6. The University of Queensland, School of Medicine, Brisbane, Australia.
Abstract
BACKGROUND: Conformal radiotherapy modalities may minimize treatment toxicities. The purpose of this study was to document the extent and timing of dysphagia and related toxicities during helical intensity-modulated radiotherapy (IMRT) with chemotherapy for oropharyngeal squamous cell carcinoma (SCC). METHODS: We conducted a prospective study of 76 patients with oropharyngeal SCC undergoing helical IMRT with chemotherapy. Dysphagia and acute toxicity data were collected weekly during treatment and at 2, 4, and 12 weeks posttreatment using the Functional Oral Intake Scale, diet descriptors, and Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. RESULTS: Patients experienced maximum incidence of grade 3 dysphagia (61%), mucositis (30%), and thick saliva (38%), with grade 2 xerostomia (87%) and dysgeusia (97%). Only 14.5% were nil-by-mouth. Symptoms peaked in week 7 and improved thereafter. Grade 3 dysphagia was twice as common for T3 to T4 tumors compared with T2. CONCLUSION: Results confirm that patients with oropharyngeal SCC undergoing helical IMRT with chemotherapy continue to experience incidences of acute toxicities comparable with other conformal techniques, and need supportive cares.
BACKGROUND: Conformal radiotherapy modalities may minimize treatment toxicities. The purpose of this study was to document the extent and timing of dysphagia and related toxicities during helical intensity-modulated radiotherapy (IMRT) with chemotherapy for oropharyngeal squamous cell carcinoma (SCC). METHODS: We conducted a prospective study of 76 patients with oropharyngeal SCC undergoing helical IMRT with chemotherapy. Dysphagia and acute toxicity data were collected weekly during treatment and at 2, 4, and 12 weeks posttreatment using the Functional Oral Intake Scale, diet descriptors, and Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. RESULTS:Patients experienced maximum incidence of grade 3 dysphagia (61%), mucositis (30%), and thick saliva (38%), with grade 2 xerostomia (87%) and dysgeusia (97%). Only 14.5% were nil-by-mouth. Symptoms peaked in week 7 and improved thereafter. Grade 3 dysphagia was twice as common for T3 to T4 tumors compared with T2. CONCLUSION: Results confirm that patients with oropharyngeal SCC undergoing helical IMRT with chemotherapy continue to experience incidences of acute toxicities comparable with other conformal techniques, and need supportive cares.
Authors: Molly K Barnhart; Bena Cartmill; Elizabeth C Ward; Elizabeth Brown; Jonathon Sim; George Saade; Sandra Rayner; Rachelle A Robinson; Virginia A Simms; Robert I Smee Journal: Dysphagia Date: 2019-02-11 Impact factor: 3.438
Authors: Laura B Moroney; Elizabeth C Ward; Jennifer Helios; Jane Crombie; Clare L Burns; Claire Blake; Tracy Comans; Benjamin Chua; Lizbeth Kenny; Brett G M Hughes Journal: Support Care Cancer Date: 2019-07-27 Impact factor: 3.603